Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ASD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: ASD. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-003313-42 Sponsor Protocol Number: AGO-TEA Start Date*: 2012-03-29
    Sponsor Name:Hospital General Universitario de Alicante
    Full Title: Efficacy of agomelatine on sleep disturbance in Autism Spectrum Disorder (ASD)
    Medical condition: The treatment of sleep disorders in patients with autism spectrum disorders (ASD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001560-35 Sponsor Protocol Number: 2358 Start Date*: 2016-04-07
    Sponsor Name:Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht , the Netherlands
    Full Title: Bumetanide in Autism Medication and BIomarker study
    Medical condition: Autism Spectrum Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006531-26 Sponsor Protocol Number: 001-738 Start Date*: 2023-05-14
    Sponsor Name:Oslo University Hospital
    Full Title: A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of...
    Medical condition: Autism spectrum disorders
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004420-30 Sponsor Protocol Number: CL3-95008-002 Start Date*: 2018-10-04
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002140-88 Sponsor Protocol Number: CL04-ORY-2001 Start Date*: 2018-09-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD)...
    Medical condition: Agression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001488 Aggression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000088-12 Sponsor Protocol Number: D1443C00012 Start Date*: 2008-08-18
    Sponsor Name:Department of Psychiatry, LMU Munich
    Full Title: A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)
    Medical condition: 40 patients with Acute Stress Disorder will be recruited within 2 years. The subjects must meet DSM- IV criteria for acute stress disorder (no acute suicidality) and will be treated with Quetiapine...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020209-33 Sponsor Protocol Number: 07052010 Start Date*: 2010-10-12
    Sponsor Name:University Hospitals Leuven
    Full Title: BOsentan for Mild Pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial
    Medical condition: Repaired (after the age of 40) atrial septal defect patients older than 40 years with evidence of mild pulmonary vascular disese as assessed by bicycle stress echocardiography.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003664 Atrial septal defect LLT
    12.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002819-21 Sponsor Protocol Number: GWND19189 Start Date*: Information not available in EudraCT
    Sponsor Name:GW Research Ltd
    Full Title: An exploratory, Phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-000989-38 Sponsor Protocol Number: WP40877 Start Date*: 2019-11-04
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib, MULTICENTER, OPEN-LABEL, 6-WEEK STUDY WITH A 48 WEEK EXTENSION TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BALOVAPTAN IN CHILDREN AGES 2-4 YEARS WITH AUTISM SPECTRU...
    Medical condition: Autism spectrum disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    20.0 10037175 - Psychiatric disorders 10003805 Autism LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005388-32 Sponsor Protocol Number: ACP-103-070 Start Date*: 2022-07-05
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)
    Medical condition: Irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003080-38 Sponsor Protocol Number: GOAT_1-2_1407 Start Date*: 2015-06-26
    Sponsor Name: Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour
    Full Title: Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD)
    Medical condition: - Obsessive-compulsive disorder - Autistic Diorder, Aspergers' Disorder, PDD NOS
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-004419-38 Sponsor Protocol Number: CL3-95008-001 Start Date*: 2018-10-04
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003524-20 Sponsor Protocol Number: BP41316 Start Date*: 2020-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participant...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000723-40 Sponsor Protocol Number: 331-201-00148 Start Date*: 2024-06-13
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
    Medical condition: Irritability Associated With Autism Spectrum Disorder (ASD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005452-26 Sponsor Protocol Number: SMR-2728 Start Date*: 2015-11-19
    Sponsor Name:OptiNose AS
    Full Title: A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate vari...
    Medical condition: Autism spectrum disorder
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Adults Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022511-18 Sponsor Protocol Number: X04 Start Date*: 2011-04-05
    Sponsor Name:Albert-Ludwig University Freiburg, Laboratory for Biological and Personality Psychology
    Full Title: Behavioral effects and neural correlates of oxytocin on social attention [Verhaltenseffekte und neuronales Korrelat von Oxytocin im Kontext sozialer Aufmerksamkeit]
    Medical condition: subjects with autism spectrum disorder and neurotypical controls
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063844 Autism spectrum disorder LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005742-38 Sponsor Protocol Number: SANTA2012 Start Date*: 2013-05-02
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Early phase triple blind placebo controlled RCT of simvastatin treatment for autism in young children with Neurofibromatosis Type 1
    Medical condition: Neurofibromatosis Type 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008380-94 Sponsor Protocol Number: Sternumhaavapuudutus Start Date*: 2009-10-05
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Jatkuvan haavapuudutuksen vaikutukset tavanomaiseen kipulääkitykseen lapsipotilailla sydänleikkauksen jälkeen
    Medical condition: Tutkittavilla lapsilla on leikkaushoitoa vaativa sydämen eteisten tai kammioiden välinen aukko
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047301 Ventricular septal defect repair LLT
    9.1 10003667 Atrial septal defect repair LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender:
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-003173-22 Sponsor Protocol Number: BP30153 Start Date*: 2020-11-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age...
    Medical condition: Autism Spectrum Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:00:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA